Sch 1 Update- BBI Holdings

RNS Number:4340W
AIM
11 May 2007


 ANNOUNCEMENT TO BE MADE BY THE AIM APPLICANT PRIOR TO ADMISSION IN ACCORDANCE WITH RULE 2 OF THE AIM RULES FOR
                                             COMPANIES ("AIM RULES")

COMPANY NAME:
BBI Holdings plc


COMPANY REGISTERED OFFICE ADDRESS AND IF DIFFERENT, COMPANY TRADING ADDRESS (INCLUDING POSTCODES) :
Golden Gate
Ty Glas Avenue
Llanishen
Cardiff CF14 5DX


COUNTRY OF INCORPORATION:
United Kingdom


COMPANY WEBSITE ADDRESS CONTAINING ALL INFORMATION REQUIRED BY AIM RULE 26:
www.britishbiocell.com


COMPANY BUSINESS (INCLUDING MAIN COUNTRY OF OPERATION) OR, IN THE CASE OF AN INVESTING COMPANY, DETAILS OF ITS
INVESTING STRATEGY).  IF THE ADMISSION IS SOUGHT AS A RESULT OF A REVERSE TAKE-OVER UNDER RULE 14, THIS SHOULD BE
STATED:
The application for admission is the result of a reverse takeover of Theratase plc by BBI Holdings plc.

BBI is involved in the development and manufacture of rapid test diagnostic products. BBI derives income from
four core areas: the manufacture and supply of gold colloids and conjugates; contract product development; rapid
test manufacture; and diabetes healthcare. Tests are currently being developed and/or manufactured for, amongst
others, food borne pathogens, bacteria in blood platelets, a range of allergens and drugs of abuse. In addition,
the BBI Group is developing in-house proprietary technology for application in diagnostic products.

Theratase is engaged in the manufacture of specialist naturally derived enzymes which are sold to the world's
healthcare market, in particular the diagnostic and therapeutic segments. Enzymes are proteins which are the
body's biological catalysts, driving complex reactions that occur in all living organisms. The Theratase Group's
products are purified from a variety of naturally sourced raw materials including plant and animal tissue and
microbial matter. The specification and treatment of these materials is of crucial importance, and Theratase
maintains a close working relationship with its suppliers, who come from all over the world including the UK,
Brazil, Australia, New Zealand, and South Africa. Theratase utilises a variety of sophisticated extraction,
filtration and chromatography techniques to isolate the required enzyme or enzymes from the initial material.

The Theratase Group has two main trading subsidiaries, each of which operates a full service facility with their
own production, development, marketing, and distribution teams. The two trading subsidiaries are Biozyme
Laboratories Limited, whose facility in the UK is based in Blaenavon in South Wales; and Seravac Biotech (Pty)
Ltd, whose facility is in the Cape Town suburb of Epping, in South Africa. The two trading subsidiaries share a
US marketing office in San Diego, California, and there is a head office in central London which will close if
the Acquisition completes.


DETAILS OF SECURITIES TO BE ADMITTED INCLUDING ANY RESTRICTIONS AS TO TRANSFER OF THE SECURITIES (i.e. where
known, number and type of shares, nominal value and issue price to which it seeks admission and the number and
type to be held as treasury shares):
42,544,770 ordinary shares of 2.5p each


CAPITAL TO BE RAISED ON ADMISSION (IF APPLICABLE) AND ANTICIPATED MARKET CAPITALISATION ON ADMISSION:
N/A


PERCENTAGE OF AIM SECURITIES NOT IN PUBLIC HANDS AT ADMISSION:
19.34%


DETAILS OF ANY OTHER EXCHANGE OR TRADING PLATFORM TO WHICH THE AIM SECURITIES (OR OTHER SECURITIES OF THE
COMPANY) ARE OR WILL BE ADMITTED OR TRADED:
N/A

FULL NAMES AND FUNCTIONS OF DIRECTORS AND PROPOSED DIRECTORS (underlining the first name by which each is known
or including any other name by which each is known):
David Eric Evans, Non-Executive Chairman
Julian Huw Baines, Chief Executive Officer
Richard Lewis Lamotte, Executive Director
Kevin William Wilson, Non-Executive Director
Jonathan David Leigh Gregory, Non-Executive Director
Philip Percival, Proposed Non-Executive Director
Dr John Chesham, proposed Executive Director
Colin David Anderson, proposed Finance Director


FULL NAMES AND HOLDINGS OF SIGNIFICANT SHAREHOLDERS EXPRESSED AS A PERCENTAGE OF THE ISSUED SHARE CAPITAL, BEFORE
AND AFTER ADMISSION (underlining the first name by which each is known or including any other name by which each
is known):




NAMES OF ALL PERSONS TO BE DISCLOSED IN ACCORDANCE WITH SCHEDULE 2, PARAGRAPH (H) OF THE AIM RULES:





(i)    ANTICIPATED ACCOUNTING REFERENCE DATE

(ii)   DATE TO WHICH THE MAIN FINANCIAL INFORMATION IN THE ADMISSION DOCUMENT HAS BEEN PREPARED

(iii)  DATES BY WHICH IT MUST PUBLISH ITS FIRST THREE REPORTS PURSUANT TO AIM RULES 18 AND 19:
       (i)   31 March
       (ii)  For BBI 31 March 2006, for Theratase 31 September 2006
       (iii) September 30 2007, 31 December 2007 and 30 September 2008


EXPECTED ADMISSION DATE:
16 May 2007


NAME AND ADDRESS OF NOMINATED ADVISER:
Teather & Greenwood Ltd.
Beaufort House
15 St Botolph Street
London EC3A 7QR


NAME AND ADDRESS OF BROKER:
Teather & Greenwood Ltd.
Beaufort House
15 St Botolph Street
London EC3A 7QR


OTHER THAN IN THE CASE OF A QUOTED APPLICANT, DETAILS OF WHERE (POSTAL OR INTERNET ADDRESS) THE ADMISSION
DOCUMENT WILL BE AVAILABLE FROM, WITH A STATEMENT THAT THIS WILL CONTAIN FULL DETAILS ABOUT THE APPLICANT AND THE
ADMISSION OF ITS SECURITIES:
Teather & Greenwood Ltd.
Beaufort House
15 St Botolph Street
London EC3A 7QR


DATE OF NOTIFICATION:
11 May 2007


NEW/ UPDATE:
UPDATE








                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

AIMEAPSFFFXXEEE